4 research outputs found
Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn's disease
BACKGROUND & AIMS: Vedolizumab is a gut-selective monoclonal antibody for the treatment of moderately to severely active Crohn's disease (CD). We performed a prospective study of endoscopic, radiologic, and histologic healing in patients with CD who received vedolizumab therapy. METHODS: We performed a phase 3b, open-label, single-group study of 101 patients with at least 3 months of active CD (a CD Activity Index [CDAI] score of 220-450, a simple endoscopic score for CD [SES-CD] of 7 or more, 1 or more mucosal ulcerations [identified by endoscopy], and failure of conventional therapy) from March 2015 through December 2017. Among the patients enrolled, 54.5% had previous failure of 1 or more tumor necrosis factor (TNF) antagonists and 44.6% had severe endoscopic disease activity (SES-CD scores above 15) at baseline. Participants received vedolizumab (300 mg intravenously) at weeks 0, 2, and 6, and then every 8 weeks thereafter, for 26 weeks (primary study) or 52 weeks (substudy, 56 patients). The primary endpoint at week 26 was endoscopic remission (SES-CD score of 4 or less); other endpoints included endoscopic response (50% reduction in SES-CD), radiologic remission (magnetic resonance index of activity score below 7), and histologic response (modified global histologic disease activity score of 4 or less). RESULTS: At week 26, 11.9% of patients were in endoscopic remission (95% confidence interval [CI] 6.3-9.8); at week 52, 17.9% of the patients were in endoscopic remission (95% CI 8.9-30.4). Higher proportions of patients naïve to TNF antagonists achieved endoscopic remission than patients with TNF-antagonist-failure at weeks 26 and 52. Higher proportion of patients with moderate CD (SES-CD scores, 7-15) achieved endoscopic remission at weeks 26 and 52 than patients with severe CD (SES-CD scores above 15). The proportion of patients with complete mucosal healing increased over time, with greater rates of healing in the colon than in the ileum. Remission was detected by magnetic resonance enterography in 21.9% of patients at week 26 (95% CI 9.3-40.0) and in 38.1% at week 52 (95% CI 18.1-61.6). At week 26, 24.4% of patients had a histologic response in the colon (95% CI 15.3-35.4) and 28.3% of patients had a histologic response in the ileum (95% CI 17.5-41.4). At week 52, 20.5% of patients had a histologic response in the colon (95% CI 9.8-35.3) and 34.3% of patients had a histologic response in the ileum (95% CI 19.1-52.2). There were no notable safety issues, including worsening of extraintestinal manifestations. CONCLUSIONS: In a phase 3b trial, we found that 26 and 52 weeks of treatment with vedolizumab (300 mg, at weeks 0, 2, and 6, and then every 8 weeks thereafter) induces endoscopic, radiologic, and histologic healing in patients with moderately to severely active CD. ClinicalTrials.gov no: NCT02425111. ispartof: GASTROENTEROLOGY vol:157 issue:4 pages:1007-+ ispartof: location:United States status: publishe
Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease
BACKGROUND & AIMS: Vedolizumab is a gut-selective monoclonal antibody for the treatment of moderately to severely active Crohn's disease (CD). We performed a prospective study of endoscopic, radiologic, and histologic healing in patients with CD who received vedolizumab therapy. METHODS: We performed a phase 3b, open-label, single-group study of 101 patients with at least 3 months of active CD (a CD Activity Index [CDAI] score of 220-450, a simple endoscopic score for CD [SES-CD] of 7 or more, 1 or more mucosal ulcerations [identified by endoscopy], and failure of conventional therapy) from March 2015 through December 2017. Among the patients enrolled, 54.5% had previous failure of 1 or more tumor necrosis factor (TNF) antagonists and 44.6% had severe endoscopic disease activity (SES-CD scores above 15) at baseline. Participants received vedolizumab (300 mg intravenously) at weeks 0, 2, and 6, and then every 8 weeks thereafter, for 26 weeks (primary study) or 52 weeks (substudy, 56 patients). The primary endpoint at week 26 was endoscopic remission (SES-CD score of 4 or less); other endpoints included endoscopic response (50% reduction in SES-CD), radiologic remission (magnetic resonance index of activity score below 7), and histologic response (modified global histologic disease activity score of 4 or less). RESULTS: At week 26, 11.9% of patients were in endoscopic remission (95% confidence interval [CI] 6.3-9.8); at week 52, 17.9% of the patients were in endoscopic remission (95% CI 8.9-30.4). Higher proportions of patients naïve to TNF antagonists achieved endoscopic remission than patients with TNF-antagonist-failure at weeks 26 and 52. Higher proportion of patients with moderate CD (SES-CD scores, 7-15) achieved endoscopic remission at weeks 26 and 52 than patients with severe CD (SES-CD scores above 15). The proportion of patients with complete mucosal healing increased over time, with greater rates of healing in the colon than in the ileum. Remission was detected by magnetic resonance enterography in 21.9% of patients at week 26 (95% CI 9.3-40.0) and in 38.1% at week 52 (95% CI 18.1-61.6). At week 26, 24.4% of patients had a histologic response in the colon (95% CI 15.3-35.4) and 28.3% of patients had a histologic response in the ileum (95% CI 17.5-41.4). At week 52, 20.5% of patients had a histologic response in the colon (95% CI 9.8-35.3) and 34.3% of patients had a histologic response in the ileum (95% CI 19.1-52.2). There were no notable safety issues, including worsening of extraintestinal manifestations. CONCLUSIONS: In a phase 3b trial, we found that 26 and 52 weeks of treatment with vedolizumab (300 mg, at weeks 0, 2, and 6, and then every 8 weeks thereafter) induces endoscopic, radiologic, and histologic healing in patients with moderately to severely active CD. ClinicalTrials.gov no: NCT02425111.status: publishe
Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease
Made available in DSpace on 2015-07-03T12:34:37Z (GMT). No. of bitstreams: 2
license.txt: 1914 bytes, checksum: 7d48279ffeed55da8dfe2f8e81f3b81f (MD5)
elisabeth_sampaioetal_IOC_2014.pdf: 526594 bytes, checksum: 18ca5c7823941cadbe16275c4fdf4bce (MD5)
Previous issue date: 2014National Institute of Allergy and Infectious Diseases. Laboratory of Clinical Infectious Diseases. Bethesda, MD, USA.National Institute of Allergy and Infectious Diseases. Biostatistics Research Branch. USA.Bethesda, MD, USA.National Institute of Allergy and Infectious Diseases. Laboratory of Clinical Infectious Diseases. Bethesda, MD, USA.National Institute of Allergy and Infectious Diseases. Laboratory of Clinical Infectious Diseases. Bethesda, MD, USA.National Institute of Allergy and Infectious Diseases. Laboratory of Clinical Infectious Diseases. Bethesda, MD, USA.National Institute of Deafness and Other Communication Disorders. Otolaryngology Branch. Bethesda, MD, USA.National Institute of Deafness and Other Communication Disorders. Otolaryngology Branch. Bethesda, MD, USA.National Institutes of Health (NIH) . Department of Radiology and Imaging Sciences. Bethesda, MD, USA.Harvard Medical School. Brigham and Women’s Hospital. Department of Radiology. Boston, Massachussets, USA.National Institutes of Health. Clinical Center. Department of Laboratory Medicine. Microbiology Service. Bethesda, Maryland, USA.National Institute of Allergy and Infectious Diseases. Laboratory of Clinical Infectious Diseases. Bethesda, MD, USA.National Institute of Allergy and Infectious Diseases. Laboratory of Clinical Infectious Diseases. Bethesda, MD, USA.National Institutes of Health. Clinical Center. Department of Laboratory Medicine. Microbiology Service. Bethesda, Maryland, USA.National Institute of Allergy and Infectious Diseases. Laboratory of Clinical Infectious Diseases. Bethesda, MD, USA.National Institute of Allergy and Infectious Diseases. Laboratory of Clinical Infectious Diseases. Bethesda, MD, USA.Rationale: Treatment of pulmonary nontuberculous mycobacteria,
especially Mycobacterium abscessus, requires prolonged, multidrug
regimens with high toxicity and suboptimal efficacy. Options for
refractory disease are limited.
Objectives: We reviewed the efficacy and toxicity of inhaled
amikacin in patients with treatment-refractory nontuberculous
mycobacterial lung disease.
Methods: Records were queried to identify patients who
had inhaled amikacin added to failing regimens. Lower
airway microbiology, symptoms, and computed tomography
scan changes were assessed together with reported toxicity.
Measurements and Main Results: The majority (80%)
of the 20 patients who met entry criteria were women; all had
bronchiectasis, two had cystic fibrosis and one had primary
ciliary dyskinesia. At initiation of inhaled amikacin, 15 were
culture positive for M. abscessus and 5 for Mycobacterium avium
complex and had received a median (range) of 60 (6, 190) months
of mycobacterial treatment. Patients were followed for a median of
19 (1, 50) months. Eight (40%) patients had at least one negative
culture and 5 (25%) had persistently negative cultures. A decrease
in smear quantity was noted in 9 of 20 (45%) and in mycobacterial
culture growth for 10 of 19 (53%). Symptom scores improved in
nine (45%), were unchanged in seven (35%), and worsened in four
(20%). Improvement on computed tomography scans was noted
in 6 (30%), unchanged in 3 (15%), and worsened in 11 (55%).
Seven (35%) stopped amikacin due to: ototoxicity in two (10%),
hemoptysis in two (10%), and nephrotoxicity, persistent dysphonia,
and vertigo in one each.
Conclusions: In some patients with treatment-refractory
pulmonary nontuberculous mycobacterial disease, the addition
of inhaled amikacin was associated with microbiologic and/or
symptomatic improvement; however, toxicity was common.
Prospective evaluation of inhaled amikacin for mycobacterial
disease is warranted